Personal information

Emails & domains

Verified email addresses

Activities

Collapse all

Employment (1)

Renmin Hospital of Wuhan University: Wuhan, CN

Employment
Source: Self-asserted source
Jinzhuo Ning

Works (10)

TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling.

Journal of translational medicine
2024-05-21 | Journal article
DOI: 10.1186/s12967-024-05273-w
PMID: 38773612
PMC: PMC11110379
Contributors: Zheng D; Ning J; Deng H; Ruan Y; fan cheng
Source: Self-asserted source
Jinzhuo Ning

AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.

Journal of translational medicine
2024-03-21 | Journal article
DOI: 10.1186/s12967-024-05099-6
PMID: 38515112
PMC: PMC10956193
Contributors: Li L; Jiang P; Hu W; Zou F; Li M; Rao T; Ruan Y; Yu W; Ning J; fan cheng
Source: Self-asserted source
Jinzhuo Ning

EXO1/P53/SREBP1 axis-regulated lipid metabolism promotes prostate cancer progression.

Journal of translational medicine
2024-01-26 | Journal article
DOI: 10.1186/s12967-023-04822-z
PMID: 38279172
PMC: PMC10811948
Contributors: Wang Z; Chao Z; Wang Q; Zou F; Song T; Xu L; Ning J; fan cheng
Source: Self-asserted source
Jinzhuo Ning

FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression.

Journal of experimental & clinical cancer research : CR
2023-11-02 | Journal article
DOI: 10.1186/s13046-023-02860-5
PMID: 37915048
PMC: PMC10621219
Contributors: Hu WM; Li M; Ning JZ; Tang YQ; Song TB; Li LZ; Zou F; Cheng F; Yu WM
Source: Self-asserted source
Jinzhuo Ning

FAP promotes clear cell renal cell carcinoma progression via activating the PI3K/AKT/mTOR signaling pathway.

Cancer cell international
2023-09-27 | Journal article
DOI: 10.1186/s12935-023-03073-8
PMID: 37752545
PMC: PMC10523722
Contributors: Jiang K; Xu LZ; Ning JZ; Cheng F
Source: Self-asserted source
Jinzhuo Ning

GREM1 is a potential biomarker for the progression and prognosis of bladder cancer.

World journal of surgical oncology
2023-08-22 | Journal article
DOI: 10.1186/s12957-023-03128-0
PMID: 37605239
PMC: PMC10463405
Contributors: Jiang PC; Xu LZ; Ning JZ; Cheng F
Source: Self-asserted source
Jinzhuo Ning

FLRT2 suppresses bladder cancer progression through inducing ferroptosis.

Journal of cellular and molecular medicine
2023-07-21 | Journal article
DOI: 10.1111/jcmm.17855
PMID: 37480224
PMC: PMC10902570
Contributors: Jiang P; Ning J; Yu W; Rao T; Ruan Y; fan cheng
Source: Self-asserted source
Jinzhuo Ning

Oleuropein attenuates testicular ischemia-reperfusion by inhibiting apoptosis and inflammation.

Tissue & cell
2022-07-27 | Journal article
DOI: 10.1016/j.tice.2022.101876
PMID: 35914339
Contributors: Xu LZ; He KX; Ning JZ; Cheng F
Source: Self-asserted source
Jinzhuo Ning

MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.

Journal of clinical laboratory analysis
2022-03-18 | Journal article
DOI: 10.1002/jcla.24360
PMID: 35303365
PMC: PMC8993605
Contributors: LI ZHE XU; Ning JZ; Ruan Y; Cheng F
Source: Self-asserted source
Jinzhuo Ning

MiR-25 regulates cell proliferation and metastasis in bladder urothelial carcinoma.

Journal of Cancer
2021-09-21 | Journal article
DOI: 10.7150/jca.62743
PMID: 34659560
PMC: PMC8517995
Contributors: Ning JZ; Chu CM; Du Y; Zuo L
Source: Self-asserted source
Jinzhuo Ning
How many people are using ORCID?